PhD
Ario
de Marco
no.:
32943
researcher – active in research organisation
Code |
Science |
Field |
Subfield |
1.04.00
|
Natural sciences and mathematics
|
Chemistry
|
|
4.06.02
|
Biotechnical sciences
|
Biotechnology
|
Bio-engineering
|
Code |
Science |
Field |
B001
|
Biomedical sciences
|
General biomedical sciences
|
antibodies, proteins, comparative oncology
Data for the last 5 years (citations for the last 10 years) on
October 15, 2025;
Data for score A3 calculation refer to period
2020-2024
(2021, 2022, 2023)
Database |
Linked records |
Citations |
Pure citations |
Average pure citations |
WoS |
137
|
4,292
|
3,744
|
27.33
|
Scopus |
142
|
4,894
|
4,249
|
29.92
|
Mentoring junior researchers
no.
|
Name and surname
|
Type
|
Period
|
Code
|
1
|
PhD Claudia D Ercole
|
Bologna doctoral studies
|
10/1/2020
-
9/30/2024
|
54824
|
Doctoral dissertations and other final papers
Show
ARIS research and infrastructure programmes
Legend
Curriculum vitae - Ario de Marco, PhD Dr Ing
e-mail:ario.demarco@ung.si
Lab of Environmental and Life Sciences, University of Nova Gorica
Vipavska cesta 13, S-5000, Nova Gorica, Slovenia
Education
2017. Dr. Ing. in Landscape Architecture Technical University of Munich (TUM), Munich,
Germany
1993 PhD in Plant Physiology and Biochemistry, University of Udine, Italy, TH Darmstadt,
Germany
Employment
Head of the Protein Expression Unit at EMBL (Heidelberg), Head of the Protein Chemistry
Unit at IFOM-IEO Campus (Milano), Director of the therapeutic antibody platform at Institut
Curie (Paris).
At University of Nova Gorica since 2010
Scientific interests and expertise
- Chaperone-assisted recombinant protein expression. Combinations of both molecular and
chemical chaperones have been optimized to improve the yields of functional recombinant
proteins in bacteria
- Recombinant protein aggregates and protein quality evaluation. Both the biotechnological
aspects and the issues related to the quality of proteins used as intermediate reagents in
research (analytical controls, minimal information, standardized annotation) are considered
- Recombinant antibody technology. We generated the first phage display naïve library of
antibodies in single-domain format and demonstrated its effectiveness to isolate specific
and highly affine binders for tumor biomarkers. A wide spectrum of vectors has been
developed to produce antibodies fused to tags optimized for different applications and the
panning conditions have been set to pan directly on cells, extracellular vesicles, protoplasts,
microalgae, cyanobacteria, and to recover epitope-specific binders
- Nanobody and alternative scaffold optimization by combined structural and in silico
approaches
We were not given permission by the researcher to publish data.